医疗健康（980016）指数十大成份股详情如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，1月5日，医疗健康（980016）指数报收于6299.52点，涨3.48%，成交383.49亿元，换手 率1.16%。当日该指数成份股中，上涨的有47家，百济神州以12.02%的涨幅领涨，下跌的有3家，常山 药业以1.0%的跌幅领跌。 资金流向方面，医疗健康（980016）指数成份股当日主力资金净流入合计9.47亿元，游资资金净流出合 计11.15亿元，散户资金净流入合计1.68亿元。成份股资金流向详情见下表： ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300255 证券简称：常山药业 公告编号：2026-1 河北常山生化药业股份有限公司 关于为全资子公司提供担保的进展公告 一、担保情况概述 河北常山生化药业股份有限公司（以下简称公司）于 2025 年 5 月 19 日召开 的 2024 年度股东大会审议并通过《关于提供担保额度预计的议案》，同意公司为 全资子公司河北常山凯库得生物技术有限公司（以下简称凯库得）借款融资提供 不超过 3.6 亿元的担保额度，上述额度期限自股东大会审议通过之日起至 2025 年度股东大会之日。具体内容详见公司刊登于巨潮资讯网的《关于提供担保额度 预计的公告》（公告编号：2025-14）。 二、担保进展 2026 年 1 月 1 日，公司与中国农业银行股份有限公司正定县支行（以下简 称农业银行）签订了《保证合同》，公司为凯库得与农业银行签订的固定资产借 款合同下 545.53 万元的本金及利息提供连带责任保证。 本次担保事项在已经审议的年度担保额度范围内，无需再提交公司董事会或 股东大会审议。 三、被担保人基本情况 1．企业 ...

证券日报网讯 12月30日，常山药业发布公告称，公司第六届董事会第六次会议审议通过《关于吸收合 并全资子公司的议案》，拟整体吸收合并河北梅山多糖多肽科技有限公司，合并后后者将注销，授权董 事长及管理层办理相关税务、工商等全部事宜。 （文章来源：证券日报） ...

Group 1 - The company Changshan Pharmaceutical held its sixth board meeting on December 30, 2025, to discuss the proposal for the absorption and merger of its wholly-owned subsidiary [1] - The meeting was conducted in a hybrid format, combining in-person attendance and remote voting [1] Group 2 - A new type of chip has been developed in China, which aims to bypass the restrictions imposed by lithography machines [1] - This new chip supports AI training and embodied intelligence and can be mass-produced using mature processes of 28 nanometers and above [1]

Core Viewpoint - Changshan Pharmaceutical (300255.SZ) plans to optimize its asset allocation and reduce management costs by absorbing its wholly-owned subsidiary, Hebei Meishan Polysaccharide Peptide Technology Co., Ltd. (Meishan Technology) [1] Group 1 - The absorption merger will result in the legal cancellation of Meishan Technology [1] - All business operations, assets, debts, and other rights and obligations of Meishan Technology will be inherited by the company [1]

证券代码：300255 证券简称：常山药业 公告编号：2025-53 河北常山生化药业股份有限公司 关于吸收合并全资子公司的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、吸收合并情况概述 河北常山生化药业股份有限公司（以下简称公司）于 2025 年 12 月 30 日召 开的第六届董事会第六次会议审议通过了《关于吸收合并全资子公司的议案》。 为进一步优化公司资产配置，降低管理成本，拟以公司为主体吸收合并全资子公 司河北梅山多糖多肽科技有限公司（以下简称梅山科技）。吸收合并完成后，梅 山科技将依法注销，梅山科技全部业务、资产、债权、债务及其他一切权利和义 务由公司依法承继。 本次吸收合并事项不构成关联交易，不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。根据《深圳证券交易所创业板股票上市规则》《公司 章程》的相关规定，该事项属于公司董事会审批权限，无需提交股东会审议。 二、合并双方基本情况 （一）合并方基本情况 1．公司名称：河北常山生化药业股份有限公司 2．企业类型：其他股份有限公司（上市） 3．注册地址：中国（河北）自由贸易试验区正定 ...

会议以记名投票方式对各项议案进行表决，审议通过如下议案： 二、董事会会议审议情况 1．审议通过《关于吸收合并全资子公司的议案》 证券代码：300255 证券简称：常山药业 公告编号：2025-52 河北常山生化药业股份有限公司 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 河北常山生化药业股份有限公司（以下简称公司）第六届董事会第六次会议 于 2025 年 12 月 30 日在公司办公楼会议室现场结合通讯表决的方式召开。本次 会议于 2025 年 12 月 26 日以邮件或直接送达的方式确保每一位董事收到本次会 议通知。与会的各位董事均已知悉与所议事项相关的必要信息。会议应参与表决 董事 6 名，实际参与表决董事 6 名。本次会议由公司董事长高晓东先生主持，符 合《公司法》及《公司章程》等规定。 1．第六届董事会第六次会议决议。 河北常山生化药业股份有限公司董事会 2025 年 12 月 30 日 公司通过整体吸收合并的方式合并全资子公司河北梅山多糖多肽科技有限 公司，合并完成后公司存续经营，河北梅山多 ...

Group 1 - The core viewpoint of the news is that Changshan Pharmaceutical's stock has experienced a decline, with significant trading activity and high financing levels, indicating potential investor concerns [1][2] - On December 29, Changshan Pharmaceutical's stock fell by 2.39%, with a trading volume of 743 million yuan. The net financing buy was negative at 1.09 million yuan, with a total financing balance of 2.628 billion yuan, accounting for 4.63% of the circulating market value [1] - The company has a high financing balance that exceeds the 90th percentile of the past year, indicating elevated levels of investor leverage [1] Group 2 - As of December 19, the number of shareholders in Changshan Pharmaceutical decreased by 4.57% to 39,600, while the average circulating shares per person increased by 4.79% to 23,203 shares [2] - For the period from January to September 2025, Changshan Pharmaceutical reported a revenue of 681 million yuan, a year-on-year decrease of 13.11%, and a net profit attributable to shareholders of -44.82 million yuan, a decline of 714.77% [2] - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.595 million yuan distributed over the last three years [3]

Group 1 - The A-share market saw significant gains on December 17, with the Shanghai Composite Index rising over 1% and the ChiNext Index increasing by more than 3%, driven by active performances from stocks like Tianfu Communication and New Yi Sheng [1] - On December 15, the ChiNext Index underwent a sample stock adjustment, adding eight new companies, including Shuanglin Co., Changshan Pharmaceutical, and Fulin Precision, which increased the weight of strategic emerging industries in the index to 93% [1] - The newly adjusted sample companies reported a year-on-year revenue growth of 16% and a net profit growth of 24% for the first three quarters, with R&D expenses increasing by 13%, highlighting a strong focus on innovation [1] Group 2 - The low-cost broad-based ChiNext ETF, Guangfa (159952), attracted significant net inflows, exceeding 13.4 billion yuan, providing investors with a cost-effective tool for investing in leading companies in the ChiNext market [2] - Current market conditions, characterized by a combination of overseas easing and domestic supportive policies, are favorable for risk assets, suggesting a potential for a cross-year market rally [2] - Looking ahead to next year, as corporate earnings continue to recover, the market structure is expected to evolve from a focus on technology to a more balanced performance across various sectors, with key themes including artificial intelligence, anti-involution, and new energy [2]

Group 1 - The core point of the article is the significant adjustment of sample stocks in major A-share indices, which is expected to lead to substantial passive fund reallocations and potentially guide active fund investments towards "new quality productivity" sectors [1][11][12]. Group 2 - The Shenzhen Stock Exchange announced that as of December 15, the Shenzhen Component Index replaced 17 stocks, the ChiNext Index replaced 8 stocks, the Shenzhen 100 Index replaced 7 stocks, and the ChiNext 50 Index replaced 5 stocks [2][3][4]. - The adjustments reflect a shift towards industries related to "new quality productivity," with traditional sectors and low-growth companies being removed from the indices [5][15]. Group 3 - The adjusted indices show a significant increase in the weight of strategic emerging industries, with the ChiNext Index's weight reaching 93%, the Shenzhen 100 Index at 81%, and the ChiNext 50 Index at 98% [5][19]. - The new stocks added generally have market capitalizations between 5 billion to 80 billion yuan and exhibit strong growth characteristics, with many showing revenue and net profit compound annual growth rates exceeding 20% [5][15]. Group 4 - The total scale of index funds tracking the Shenzhen Component Index, ChiNext Index, Shenzhen 100, and ChiNext 50 exceeds 250.728 billion yuan, indicating a large amount of passive funds that will be affected by these adjustments [7][18]. - The adjustments are expected to create a divergence in stock performance, with newly added stocks likely to see increased trading activity due to passive fund inflows, while removed stocks may face selling pressure [7][18]. Group 5 - Nearly 60% of the companies in the adjusted Shenzhen Component Index have implemented quality improvement and stock repurchase plans, with the total dividends from Shenzhen 100 companies this year amounting to 302.2 billion yuan, accounting for 55% of the total dividends in the Shenzhen market [19].